Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.
about
Cryptococcus-Related Immune Reconstitution Inflammatory Syndrome (IRIS): Pathogenesis and its Clinical ImplicationsPaucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndromeReal-Time Imaging of Interactions of Neutrophils with Cryptococcus neoformans Demonstrates a Crucial Role of Complement C5a-C5aR SignalingCryptococcal interactions with the host immune system.History of medical mycology in the united states.Extracellular vesicles from Cryptococcus neoformans modulate macrophage functionsCharacterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsuleBivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule.Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular material of Cryptococcus neoformans.Mannan-specific immunoglobulin G antibodies in normal human serum accelerate binding of C3 to Candida albicans via the alternative complement pathway.Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificityModulation of C5aR expression on human neutrophils by encapsulated and acapsular Cryptococcus neoformans.Cryptococcus inositol utilization modulates the host protective immune response during brain infectionBinding of Cryptococcus neoformans by human cultured macrophages. Requirements for multiple complement receptors and actin.Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformansDifferential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans.CPS1, a homolog of the Streptococcus pneumoniae type 3 polysaccharide synthase gene, is important for the pathobiology of Cryptococcus neoformansAspergillus fumigatus complement inhibitor: production, characterization, and purification by hydrophobic interaction and thin-layer chromatography.Distinct characteristics of initiation of the classical and alternative complement pathways by Candida albicans.Binding of Cryptococcus neoformans to heterologously expressed human complement receptors.Activation, binding, and processing of complement component 3 (C3) by Blastomyces dermatitidis.Secretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cryptococcus neoformans.Role of phagocytosis in the virulence of Cryptococcus neoformans.Cryptococcal genotype influences immunologic response and human clinical outcome after meningitis.Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans.Activation of C3 and binding to Aspergillus fumigatus conidia and hyphae.Protective immunity against cryptococcus neoformans infection.The capsule of the fungal pathogen Cryptococcus neoformans.Role of dendritic cell-pathogen interactions in the immune response to pulmonary cryptococcal infection.Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes.Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains.Activation of the complement system by pathogenic fungi.Influence of opsonization conditions on C3 deposition and phagocyte binding of large- and small-capsule Cryptococcus neoformans cells.Kinetic analysis of the amplification phase for activation and binding of C3 to encapsulated and nonencapsulated Cryptococcus neoformans.Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans.Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans.Accelerated decay of C3b to iC3b when C3b is bound to the Cryptococcus neoformans capsule.Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan.Innate Immune Responses to Cryptococcus.
P2860
Q24629367-BCCB7296-F104-407F-A2B7-C0AB4B62C61DQ24630287-9572EEAC-C400-4A52-BAC7-88371BA9F9F0Q27322596-4228B01E-BC68-4FC5-9E5B-DB41924FBFBFQ30387948-AE01803C-4E06-4EB4-91C4-87DFAB890D53Q30452877-523697E4-6090-4DD9-A54D-54E745A7B02CQ30493958-B80136E3-97C2-49A7-A4D4-D5D0B9265AFAQ33752366-D4088420-08D0-4B24-944F-98190E966916Q33752377-39C33DA4-16A1-48A9-B287-09D4B10D6E0DQ33762293-F8D49C0B-FC1E-451B-BE94-44A8027F494FQ33765773-85BC6EFD-00DC-4929-B54E-CFBFFA66E737Q34121516-015FE545-4A66-46B0-98C9-C4FA5F8CA87EQ34123230-0C49E0B4-42BA-4722-9951-73229175A94BQ34125581-1D8289BD-D21E-457F-B3CF-6D47222126BCQ34234478-6580F63D-968B-4A3E-B528-F8BAC19BC45AQ34236760-DD63CD13-3F83-4A09-8C4E-08E18893931FQ34680995-D4C4A0D9-6D67-4E72-B5DE-4C971FAA8089Q34681238-386A1D18-59DC-45E5-8A9C-FA500B93E9D8Q34720974-1A10D4B4-8689-4EA8-9A03-32C3792950B7Q35107002-3068C384-EE99-440B-A922-A51B6DF93061Q35513657-DEF704CC-8F18-4F82-AE81-51CE830399C4Q35544049-EB0D221E-53E5-4773-9897-E053B9C64E69Q35547013-9F88F0AE-8573-4907-85FD-407CE9DBAA1EQ35556339-D21C1984-B155-4C77-99D4-8D98B0258907Q35911335-F01BFB77-E357-4220-8B21-A28B75EBEA5EQ36250573-2A26EF7F-1491-4E75-A17E-7FAA35F8A8A0Q36967835-36FF9D82-10BC-4086-B9CD-9BEB65C0929EQ37005496-6798CA0B-1383-4FE2-A25C-9398E8CF4389Q37181729-37560EBF-05C9-401D-8D38-F2284BCBF59EQ37337879-3FD943BC-395B-4E73-B321-2C97D1DDF165Q38644509-F3D3DF09-961E-46E9-8DF8-16C592042D7CQ39569976-4BDD33F6-006A-41D5-BA51-128123AF59B0Q39746326-D2C77B0C-BF5E-426A-B1A9-416740781EA2Q39820650-01EE8C71-5554-48A0-B13C-67343A79E151Q39825246-4122DCE9-A086-4AA4-85E1-F91189AAC510Q40147480-7EF2C7AC-2090-4C1D-B020-68C549110283Q40148722-A403E54C-BBD9-4210-8C06-760EAC43203EQ40267867-C5C1FC5A-F638-45BF-BE37-2334046A57CAQ40269086-986DA6B1-529D-4AA7-A798-B57747754553Q40374574-7056AF8B-4375-4A16-AFDC-F44D8E9E84F9Q41721935-29E0200D-81CF-4C51-8046-CF10D49D9445
P2860
Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.
description
1989 nî lūn-bûn
@nan
1989 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Activation and binding of opso ...... ed from six isolated proteins.
@ast
Activation and binding of opso ...... ed from six isolated proteins.
@en
type
label
Activation and binding of opso ...... ed from six isolated proteins.
@ast
Activation and binding of opso ...... ed from six isolated proteins.
@en
prefLabel
Activation and binding of opso ...... ed from six isolated proteins.
@ast
Activation and binding of opso ...... ed from six isolated proteins.
@en
P2093
P2860
P1476
Activation and binding of opso ...... ed from six isolated proteins.
@en
P2093
A M Schlageter
G S Pfrommer
M A Wilson
P2860
P304
P407
P577
1989-07-01T00:00:00Z